H. Lundbeck A/S
Ottiliavej 9
Valby
Copenhagen
DK-2500
Tel: 45-3630-1311
Fax: 45 3630 1940
Website: http://www.lundbeck.com/
143 articles about H. Lundbeck A/S
-
It was a slow week as far as changes were made at the executive level in the biopharma industry. Still, three companies made key appointments that will potentially spur strategic growth for stakeholders.
-
Former XTuit Pharmaceuticals Chief Executive Officer Deborah Dunsire has been appointed head of Denmark-based H. Lundbeck A/S.
-
TRINTELLIX® (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD)
5/2/2018
Takeda Pharmaceutical Company Limited and H. Lundbeck A/S announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for TRINTELLIX® (vortioxetine).
-
Lundbeck Acquires Prexton Therapeutics
3/16/2018
Lunbeck is acquiring Prexton Therapeutics BV, a 2012 spinout from Merck KgaA, and its Phase II treatment for Parkinson’s disease. -
Forbion’s Portfolio Company, Prexton Therapeutics Acquired by Lundbeck for up to EUR 905 million (USD 1.1 billion)
3/16/2018
Upfront payment of EUR 100 million plus up to EUR 805 million in development, regulatory and sales milestones; Foliglurax – a first-in-class development candidate for Parkinson’s disease in Phase II clinical development; Prexton sale marks third successful exit from Forbion’s most recent fund, Forbion III
-
Lundbeck Delivers Its Best Financial Results Following 10% Revenue Growth and 117% Growth in Net Profit
2/7/2018
Revenue reached DKK 17,234 million in 2017 representing an increase of 10% (12% in local currencies) compared to 2016 .
-
Lundbeck Enters Research Partnership on Novel Treatment of Schizophrenia
1/5/2018
New partnership with Vanderbilt University sees Lundbeck acquire an exclusive license to a research program aimed at a novel approach to treating schizophrenia.
-
Lundbeck’s Brintellix Approved in China
12/4/2017
The expected launch of Brintellix in Q2 2018 will enable Lundbeck to make an even bigger difference for the many patients and caregivers affected by depression in China.
-
Lundbeck Increases Its Share Capital by 116,330 Shares (0.0585 % of Outstanding Shares) as a Result of Exercise of Employee Warrants
11/21/2017
The increase is effected without any preemption rights for the existing shareholders of the company or others.
-
Transactions With Shares and Linked Securities in H. Lundbeck A/S Made by Executives and Their Closely Associated Parties – Nov. 17, 2017
11/17/2017
The company hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.
-
Lundbeck Increased Operating Profit (EBIT) With 126% and EPS by 182% in the First Nine Months of 2017
11/8/2017
Revenue reached DKK 12,842 million in the first nine months of 2017 representing an increase of 12% (13% in local currencies) compared to the same period last year.
-
Otsuka and Lundbeck Will Initiate a Third Phase III Trial to Evaluate Brexpiprazole in the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
11/1/2017
The trial is expected to commence during the first half of 2018.
-
Lundbeck and Otsuka Will Initiate a Third Phase III Trial to Evaluate the Use of Brexpiprazole in the Treatment of Agitation In Patients With Dementia of the Alzheimer's Type
11/1/2017
The trial is expected to commence during the first half of 2018.
-
Anders Gotzsche will serve as interim CEO while the company looks for a replacement for Kare Schultz who leaves the company Oct. 31 for the CEO position at Teva.
-
Neurological-Focused Pharmaceutical Company, H. Lundbeck A/S, Continues Use Of Medidata Solutions, Inc. Clinical Cloud With Multi-Year Partnership
10/5/2017
-
Cerveau Technologies Signs Collaboration Agreement With H. Lundbeck A/S For Novel Tau Imaging Agent
9/15/2017
-
Changes In Executive Management In H. Lundbeck A/S
9/11/2017
-
Transactions With Shares And Linked Securities In H. Lundbeck A/S Made By Executives And Their Closely Associated Parties
8/28/2017
-
H. Lundbeck A/S Increases Its Share Capital By 470,889 Shares (0.2373 % Of Outstanding Shares) As A Result Of Exercise Of Employee Warrants
8/22/2017
-
Transactions With Shares And Linked Securities In H. Lundbeck A/S Made By Executives And Their Closely Associated Parties
8/10/2017